| Rosuvastatin |
20120186 |
Starcrest, Film coated tablet, 10, mg, Pack: 30 |
Alvogen IPCo S.àr.l, Люксембург |
Synthon BV, Holand; Synthon Hispania S.L., Spain; Gemelog-BRS Kft., Hungary; Джи И Фармасютикълс ООД, България |
16.49 |
3.3 |
19.79 |
6% |
0.99 |
17.48 |
3.5 |
20.98 |
18% |
2.97 |
20.45 |
4.09 |
24.54 |
цената се заличава HCР-221/20.06.2013 |
КЦРР-1577/05.11.2012 |
21.11.2012 |
21.11.2012 |
Заличен |
1433 |
| Rosuvastatin |
20120179 |
Starcrest, Film coated tablet, 20, mg, Pack: 30 |
Alvogen IPCo S.àr.l, Люксембург |
Synthon BV, Holand; Synthon Hispania S.L., Spain; Gemelog-BRS Kft., Hungary; Джи И Фармасютикълс ООД, България |
29.94 |
5.99 |
35.93 |
6% |
1.8 |
31.74 |
6.35 |
38.09 |
18% |
5.39 |
37.13 |
7.43 |
44.56 |
цената се заличава HCР-222/20.06.2013 |
КЦРР-1577/05.11.2012 |
21.11.2012 |
21.11.2012 |
Заличен |
1434 |
| Bosentan |
EU/1/13/832/006 |
Stayveer, Film coated tablet, 125, mg, Pack: 56(in bottle) |
Janssen-Cilag International N.V., Белгия |
Haupt Pharma Wülfing GmbH, Германия |
1350.44 |
270.09 |
1620.53 |
4% |
10 |
1360.44 |
272.09 |
1632.53 |
16% |
25 |
1385.44 |
277.09 |
1662.53 |
|
НСР-18861/30.05.2019 предварително изпълнение |
30.05.2019 |
02.06.2019 |
Активен |
16512 |
| Bosentan |
EU/1/13/832/006 |
Stayveer, Film coated tablet, 125, mg, Pack: 56(in bottle) |
Janssen-Cilag International N.V., Белгия |
Haupt Pharma Wülfing GmbH, Германия |
1350.44 |
270.09 |
1620.53 |
4% |
10 |
1360.44 |
272.09 |
1632.53 |
16% |
25 |
1385.44 |
277.09 |
1662.53 |
|
НСР-18861/30.05.2019 предварително изпълнение |
30.05.2019 |
02.06.2019 |
Неактивен |
16512 |
| Bosentan |
EU/1/13/832/002 |
Stayveer, Film coated tablet, 125, mg, Pack: 56 |
Janssen-Cilag International N.V., Белгия |
Haupt Pharma Wülfing GmbH, Bethelner Landstraße 18, 31028 Gronau/Leine, Германия |
1350.44 |
270.09 |
1620.53 |
4% |
10 |
1360.44 |
272.09 |
1632.53 |
16% |
25 |
1385.44 |
277.09 |
1662.53 |
Промяна на обстоятелства НСР-18475/22.04.2019 |
НСР-11032/01.12.2016; НСР-15170/02.03.2018; НСР-18813/30.05.2019; НСР-19851/20.09.2019 |
14.06.2019 |
02.11.2019 |
Заличен |
15517 |
| Bosentan |
EU/1/13/832/002 |
Stayveer, Film coated tablet, 125, mg, Pack: 56 |
Janssen-Cilag International N.V., Белгия |
Haupt Pharma Wülfing GmbH, Bethelner Landstraße 18, 31028 Gronau/Leine, Германия |
1350.44 |
270.09 |
1620.53 |
4% |
10 |
1360.44 |
272.09 |
1632.53 |
16% |
25 |
1385.44 |
277.09 |
1662.53 |
Промяна на обстоятелства НСР-18475/22.04.2019 |
НСР-11032/01.12.2016; НСР-15170/02.03.2018; НСР-18813/30.05.2019 |
14.06.2019 |
02.07.2019 |
Неактивен |
15517 |
| Bosentan |
EU/1/13/832/002 |
Stayveer, Film coated tablet, 125, mg, Pack: 56 |
Janssen-Cilag International N.V., Белгия |
Haupt Pharma Wülfing GmbH, Bethelner Landstraße 18, 31028 Gronau/Leine, Германия |
1881.51 |
376.3 |
2257.81 |
4% |
10 |
1891.51 |
378.3 |
2269.81 |
16% |
25 |
1916.51 |
383.3 |
2299.81 |
Промяна на обстоятелства НСР-18475/22.04.2019 |
НСР-11032/01.12.2016; НСР-15170/02.03.2018 |
17.03.2018 |
02.06.2019 |
Неактивен |
15517 |
| Bosentan |
EU/1/13/832/002 |
Stayveer, Film coated tablet, 125, mg, Pack: 56 |
Marklas Nederland BV, Нидерландия |
Haupt Pharma Wülfing GmbH, Bethelner Landstraße 18, 31028 Gronau/Leine, Германия |
1881.51 |
376.3 |
2257.81 |
4% |
10 |
1891.51 |
378.3 |
2269.81 |
16% |
25 |
1916.51 |
383.3 |
2299.81 |
|
НСР-11032/01.12.2016; НСР-15170/02.03.2018 |
17.03.2018 |
02.04.2018 |
Неактивен |
15517 |
| Bosentan |
EU/1/13/832/002 |
Stayveer, Film coated tablet, 125, mg, Pack: 56 |
Marklas Nederland BV, Нидерландия |
Haupt Pharma Wülfing GmbH, Bethelner Landstraße 18, 31028 Gronau/Leine, Германия |
2272.5 |
454.5 |
2727 |
4% |
10 |
2282.5 |
456.5 |
2739 |
16% |
25 |
2307.5 |
461.5 |
2769 |
|
НСР-11032/01.12.2016 |
17.12.2016 |
02.01.2017 |
Неактивен |
15517 |
| Ertugliflozin |
EU/1/18/1267/002 |
Steglatro, Film coated tablet, 5, mg, Pack: 28 |
Merck Sharp & Dohme B.V., Нидерландия |
Schering-Plough Labo NV, Белгия |
67.2 |
13.44 |
80.64 |
4% |
2.69 |
69.89 |
13.98 |
83.87 |
16% |
10.75 |
80.64 |
16.13 |
96.77 |
|
НСР-19719/04.09.2019; НСР-20634/16.01.2020 |
19.09.2019 |
02.02.2020 |
Заличен |
16683 |
| Ertugliflozin |
EU/1/18/1267/002 |
Steglatro, Film coated tablet, 5, mg, Pack: 28 |
Merck Sharp & Dohme B.V., Нидерландия |
Schering-Plough Labo NV, Белгия |
67.2 |
13.44 |
80.64 |
4% |
2.69 |
69.89 |
13.98 |
83.87 |
16% |
10.75 |
80.64 |
16.13 |
96.77 |
|
НСР-19719/04.09.2019 |
19.09.2019 |
02.10.2019 |
Неактивен |
16683 |
| Ertugliflozin |
EU/1/18/1267/002 |
Steglatro, Film coated tablet, 5, mg, Pack: 28 |
Merck Sharp & Dohme B.V., Нидерландия |
Schering-Plough Labo NV, Белгия |
67.2 |
13.44 |
80.64 |
4% |
2.69 |
69.89 |
13.98 |
83.87 |
16% |
10.75 |
80.64 |
16.13 |
96.77 |
|
НСР-19719/04.09.2019 |
19.09.2019 |
02.10.2019 |
Неактивен |
16683 |
| Ustekinumab |
EU/1/08/494/003 |
STELARA, Solution for injection, 45, mg, Pack: 1 pre-filled syringe |
Janssen-Cilag International N.V., Белгия |
Janssen Biologics B.V.Einsteinweg 101NL-2333 CB Leiden, Холандия |
4176.48 |
835.3 |
5011.78 |
4% |
10 |
4186.48 |
837.3 |
5023.78 |
16% |
25 |
4211.48 |
842.3 |
5053.78 |
|
НСР-5746/26.02.2015.; НСР-9217/ 05.05.2016; НСР-11559/26.01.2017; НСР-14236/19.10.2017; НСР-16130/13.07.2018 (предварително изпълнение); НСР-19875/27.09.2019 |
12.10.2019 |
02.11.2019 |
Активен |
3636 |
| Ustekinumab |
EU/1/08/ 494/003 |
STELARA, Solution for injection, 45, mg, Pack: 1 pre-filled syringe |
Janssen-Cilag International N.V., Белгия |
Janssen Biologics B.V.Einsteinweg 101NL-2333 CB Leiden, Холандия |
4176.62 |
835.32 |
5011.94 |
4% |
10 |
4186.62 |
837.32 |
5023.94 |
16% |
25 |
4211.62 |
842.32 |
5053.94 |
|
НСР-5746/26.02.2015.; НСР-9217/ 05.05.2016; НСР-11559/26.01.2017; НСР-14236/19.10.2017; НСР-16130/13.07.2018 (предварително изпълнение) |
13.07.2018 |
02.08.2018 |
Неактивен |
3636 |
| Ustekinumab |
EU/1/08/ 494/003 |
STELARA, Solution for injection, 45, mg, Pack: 1 pre-filled syringe |
Janssen-Cilag International N.V., Белгия |
Janssen Biologics B.V.Einsteinweg 101NL-2333 CB Leiden, Холандия |
4515.27 |
903.05 |
5418.32 |
4% |
10 |
4525.27 |
905.05 |
5430.32 |
16% |
25 |
4550.27 |
910.05 |
5460.32 |
|
НСР-5746/26.02.2015.; НСР-9217/ 05.05.2016; НСР-11559/26.01.2017; НСР-14236/19.10.2017 |
03.11.2017 |
02.12.2017 |
Неактивен |
3636 |
| Ustekinumab |
EU/1/08/ 494/003 |
STELARA, Solution for injection, 45, mg, Pack: 1 pre-filled syringe |
Janssen-Cilag International N.V., Белгия |
Janssen Biologics B.V.Einsteinweg 101NL-2333 CB Leiden, Холандия |
4747.91 |
949.58 |
5697.49 |
4% |
10 |
4757.91 |
951.58 |
5709.49 |
16% |
25 |
4782.91 |
956.58 |
5739.49 |
|
НСР-5746/26.02.2015.; НСР-9217/ 05.05.2016; НСР-11559/26.01.2017 |
02.03.2017 |
02.03.2017 |
Неактивен |
3636 |
| Ustekinumab |
EU/1/08/ 494/003 |
STELARA, Solution for injection, 45, mg, Pack: 1 |
Janssen-Cilag International N.V., Белгия |
Janssen Biologics B.V.Einsteinweg 101NL-2333 CB Leiden, Холандия |
5050.97 |
1010.19 |
6061.16 |
4% |
10 |
5060.97 |
1012.19 |
6073.16 |
16% |
25 |
5085.97 |
1017.19 |
6103.16 |
|
НСР-5746/26.02.2015.; НСР-9217/ 05.05.2016 |
02.06.2016 |
02.06.2016 |
Неактивен |
3636 |
| Ustekinumab |
EU/1/08/ 494/003 |
STELARA, Solution for injection, 45, mg, Pack: 1 |
Janssen-Cilag International N.V., Белгия |
Janssen Biologics B.V.Einsteinweg 101NL-2333 CB Leiden, Холандия |
5083.12 |
1016.62 |
6099.74 |
4% |
10 |
5093.12 |
1018.62 |
6111.74 |
16% |
25 |
5118.12 |
1023.62 |
6141.74 |
|
НСР-5746/26.02.2015. |
12.03.2015 |
12.03.2015 |
Неактивен |
3636 |
| Ustekinumab |
EU/1/08/ 494/003 |
STELARA, Solution for injection, 45, mg, Pack: 1 |
Janssen-Cilag International N.V., Белгия |
Janssen Biologics B.V.Einsteinweg 101NL-2333 CB Leiden,Холандия |
5407.79 |
1081.56 |
6489.35 |
4% |
10 |
5417.79 |
1083.56 |
6501.35 |
16% |
25 |
5442.79 |
1088.56 |
6531.35 |
|
НСР-3654/29.05.2014 |
13.06.2014 |
13.06.2014 |
Неактивен |
3636 |
| Ustekinumab |
EU/1/08/ 494/003 |
STELARA, Solution for injection, 45, mg, Pack: 1 |
Janssen-Cilag International N.V., Белгия |
Janssen Biologics B.V.Einsteinweg 101NL-2333 CB Leiden,Холандия |
5479.92 |
1095.98 |
6575.9 |
4% |
10 |
5489.92 |
1097.98 |
6587.9 |
16% |
25 |
5514.92 |
1102.98 |
6617.9 |
|
НСР-1117/10.09.2013 |
24.09.2013 |
24.09.2013 |
Неактивен |
3636 |
| Electrolytes |
20130250 |
Sterofundin ISO, Solution for infusion, 1000 ml 6.80 g/l /0.30 g/l / 0.20 g/l / 0.37 g/l / 3.27 g/l / 0.67 g/l, ml, Pack: 1 |
B. Braun Melsungen AG, Германия |
B. Braun Melsungen AG, Германия;B. Braun Medical S.A., Испания |
5.46 |
1.09 |
6.55 |
7% |
0.38 |
5.84 |
1.17 |
7.01 |
20% |
1.09 |
6.93 |
1.39 |
8.32 |
|
НСР-6207/21.05.2015 |
04.06.2015 |
04.06.2015 |
Активен |
3080 |
| Electrolytes |
20130250 |
Sterofundin ISO, Solution for infusion, 500 ml 6.80 g/l /0.30 g/l / 0.20 g/l / 0.37 g/l / 3.27 g/l / 0.67 g/l, ml, Pack: 1 |
B. Braun Melsungen AG, Германия |
B. Braun Melsungen AG, Германия;B. Braun Medical S.A., Испания |
4.65 |
0.93 |
5.58 |
7% |
0.33 |
4.98 |
1 |
5.98 |
20% |
0.93 |
5.91 |
1.18 |
7.09 |
|
НСР-6206/21.05.2015 |
04.06.2015 |
04.06.2015 |
Активен |
3079 |
| Electrolytes |
20130250 |
Sterofundin ISO, Solution for infusion, 1000 ml 6.80 g/l /0.30 g/l / 0.20 g/l / 0.37 g/l / 3.27 g/l / 0.67 g/l, ml, Pack: 1 |
B. Braun Melsungen AG, Германия |
B. Braun Melsungen AG, Германия;B. Braun Medical S.A., Испания |
5.57 |
1.11 |
6.68 |
7% |
0.39 |
5.96 |
1.19 |
7.15 |
20% |
1.11 |
7.07 |
1.41 |
8.48 |
|
НСР-4428/07.08.2014 |
25.08.2014 |
25.08.2014 |
Неактивен |
3080 |
| Electrolytes |
20130250 |
Sterofundin ISO, Solution for infusion, 500 ml 6.80 g/l /0.30 g/l / 0.20 g/l / 0.37 g/l / 3.27 g/l / 0.67 g/l, ml, Pack: 1 |
B. Braun Melsungen AG, Германия |
B. Braun Melsungen AG, Германия;B. Braun Medical S.A., Испания |
4.75 |
0.95 |
5.7 |
7% |
0.33 |
5.08 |
1.02 |
6.1 |
20% |
0.95 |
6.03 |
1.21 |
7.24 |
|
НСР-4427/07.08.2014 |
25.08.2014 |
25.08.2014 |
Неактивен |
3079 |
| Sertraline |
20040312 |
STIMULOTON, Film coated tablet, 50, mg, Pack: 30 |
EGIS Pharmaceuticals PLC, Унгария |
EGIS Pharmaceuticals PLC, УНГАРИЯ |
6.24 |
1.25 |
7.49 |
7% |
0.44 |
6.68 |
1.34 |
8.02 |
20% |
1.25 |
7.93 |
1.59 |
9.52 |
Отхвърлена жалба от Комисия по прозрачност с решение КП-105/06.04.2015; Промяна на обстоятелства НСР-11985/10.03.2017 |
НСР-3546/16.05.2014.; HCP-6025/09.04.2015. |
02.05.2015 |
02.04.2017 |
Активен |
3783 |